Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats.
Agnieszka Nikiforuk, Piotr Popik
Psychopharmacology September 15, 2011 DOI: 10.1007/s00213-011-2487-x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled animal study Peer reviewed |
|---|---|
| Population | Male Sprague-Dawley rats |
| Interventions | Ketamine Quetiapine Sertindole |
| Dose | Ketamine 30 mg/kg; quetiapine 0.63, 1.25, or 2.5 mg/kg; sertindole 2.5 mg/kg |
| Duration | Ketamine once daily for 5 or 10 consecutive days; attentional set-shifting task performed 14 days after final ketamine dose; quetiapine or sertindole given 120 min before testing |
| Measures | Attentional set-shifting task (ASST) |
| Topics | Ketamine Esketamine |
| Keywords | Animals Rats, sprague-dawley Disease models, animal Imidazoles Indoles Dibenzothiazepines Antipsychotic agents Attention Cognition disorders Schizophrenia Dose-response relationship, drug Male Quetiapine fumarate |
| Key points | Ketamine given daily for 10 days, but not 5 days, produced a specific impairment in the extra-dimensional shift stage of an attentional set-shifting task 14 days after the last dose. Acute sertindole or quetiapine reversed this impairment, and quetiapine also improved set-shifting in cognitively unimpaired control rats. The authors argue this ketamine-induced deficit models clinically relevant cognitive dysfunction in schizophrenia. |
Abstract
Rationale: Prefrontal cortical dysfunctions, including an impaired ability to shift perceptual attentional set, are core features of schizophrenia. Nevertheless, the effectiveness of second-generation antipsychotic drugs in treating specific prefrontal dysfunctions remains equivocal.
Objectives: To model schizophrenia-like cognitive inflexibility in rats, we evaluated the effects of repeated administration of ketamine, the noncompetitive antagonist of the N-methyl-D: -aspartate receptor, after a washout period of 14 days in the attentional set-shifting task (ASST). Next, we investigated whether the atypical antipsychotics quetiapine and sertindole would alleviate the ketamine-induced set-shifting impairment.
Methods: Ketamine (30 mg/kg) was administered intraperitoneally to rats once daily for 5 or 10 consecutive days to assess its efficacy in producing cognitive impairment. The ASST was performed 14 days following the final drug administration. Quetiapine (0.63, 1.25 or 2.5 mg/kg) or sertindole (2.5 mg/kg) was administered per os 120 min before testing.
Results: The results of the present study demonstrate that ketamine treatment for 10 but not 5 days significantly and specifically impaired rats' performance in the extra-dimensional shift (EDs) stage of the ASST. This cognitive inflexibility was reversed by acute administration of sertindole or quetiapine. Quetiapine also promoted set-shifting in cognitively unimpaired control animals.
Conclusion: The data presented here show that subchronic administration of ketamine induces cognitive inflexibility after a washout period. This cognitive deficit likely reflects clinically relevant aspects of cognitive dysfunction encountered in schizophrenic patients. The beneficial effects of quetiapine on set-shifting may have therapeutic implications for the treatment of schizophrenia and other disorders associated with frontal-dependent cognitive impairments.
Comparable studies
Other preclinical and animal studies on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Rats | 2010 | Observational study | |
| Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Conscious rats | 1997 | Dose-response study with microdialysis and behavioral testing | |
| NMDAR inhibition-independent antidepressant actions of ketamine metabolites Mice | 2016 | Preclinical study | |
| The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate Spinal neurons in decerebrate or pentobarbitone-anaesthetized cats and rats | 1983 | Experimental study | |
| R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Mice | 2015 | Experimental study |
Citations in the library
Cited by 8
- Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats. Neuropsychopharmacology December 1, 2024
- Effects of acute and chronic ketamine administration on spontaneous and evoked brain activity. Brain Research 2025
- The dynamic strategy shifting task: Optimisation of an operant task for assessing cognitive flexibility in rats. Frontiers in Psychiatry 2024
- Cannabidiol reverses myeloperoxidase hyperactivity in the prefrontal cortex and striatum, and reduces protein carbonyls in the hippocampus in a ketamine-induced schizophrenia rat model. Schizophrenia Research April 1, 2025
- Psychosis: The Utility of Ketamine as a Pharmacological Model of Psychotic-like Symptoms in Rodents: A Review of Dosage Regimens Biology January 25, 2026
and 3 more in the library
Cites 3
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity. Schizophrenia Bulletin September 1, 2010
- Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance. Journal of Neuroscience Methods December 15, 2009